Printer Friendly

CELGENE APPOINTS JOHNSON & JOHNSON EXECUTIVE AS PRESIDENT AND COO

 WARREN, N.J., March 23 /PRNewswire/ -- Celgene Corporation (NASDAQ: CELG) today announced it has appointed Thomas H. Odiorne as president and chief operating officer. Mr. Odiorne brings to the company more than 20 years' experience in the pharmaceutical industry.
 "We are very fortunate to have Tom join our management team. He brings to Celgene the abilities to further expand our chiral business to help pharmaceutical companies cost-effectively develop safer and more efficacious drugs," said John Ufheil, chairman and chief executive officer of Celgene. "In addition, Tom's extensive managerial experience at Johnson & Johnson will be a tremendous asset as we implement our strategic alliance with Betz Laboratories, Inc. to commercialize our biotreatment technology."
 As president and chief operating officer, Mr. Odiorne will take charge of all business operations and will be responsible for the continued transformation of Celgene from a technology-driven company to a technology intense market-driven enterprise. Mr. Odiorne will join Celgene on April 5. On this date, he will succeed Mr. Ufheil as president. Mr. Ufheil will remain chairman and chief executive officer.
 "Celgene's technology provides unique opportunities to answer social and economic needs for toxic waste minimization and purer, less costly pharmaceuticals. This should be an exciting time in the company's development," said Mr. Odiorne.
 Prior to joining Celgene, Mr. Odiorne, 52, was president of the Pharmaceutical Development Group of Johnson & Johnson. Previously, he spent 20 years at Johnson & Johnson's McNeil Pharmaceutical Company in senior sales and marketing positions including executive director of sales and vice president of sales and marketing. Mr. Odiorne went on to become president of McNeil in 1985 with overall responsibility for management of the operations of the U.S. and Canadian companies. During this time, Mr. Odiorne was involved in the licensing of a number of products along with developing marketing strategic alliances with other companies.
 Mr. Odiorne received a B.S. education, biology, from Lamar University in Beaumont, Texas, and completed advanced studies at East Texas State University under a National Science Foundation Scholarship, studies at Harvard Business School in the Executive Program in Marketing Management, as well as the Executive Program in Business Administration at Columbia Business School.
 Celgene Corporation, based in Warren, is a chemical biotechnology company engaged in the development of proprietary biotreatment systems to degrade hazardous wastes and the development and manufacture of high- purity chiral chemicals for the pharmaceutical, agrochemical and food industries.
 -0- 3/23/93
 /CONTACT: J. L. Ufheil, chairman and CEO of Celgene, 908-271-4102; or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for Celgene/
 (CELG)


CO: Celgene Corporation ST: New Jersey IN: MTC SU: PER

GK-SM -- NY025 -- 8583 03/23/93 10:20 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 23, 1993
Words:443
Previous Article:VIDEOCART ANNOUNCES NEW CHIEF EXECUTIVE AND CORPORATE RESTRUCTURING
Next Article:BEN R. STUART JOINS CRSS BOARD OF DIRECTORS
Topics:


Related Articles
MACRONEX APPOINTS NEW PRESIDENT AND CEO
CELGENE NAMES NEW CHAIRMAN AND CHIEF EXECUTIVE
CELGENE CORPORATION NAMES JOHNSON & JOHNSON EXECUTIVE AS NEW MARKETING VICE PRESIDENT
IVAX Corporation Appoints Robert C. Strauss as President and Chief Operating Officer
Scandipharm Announc
Industry. (Personals/Personnalites).
Celgene Appoints Thomas O. Daniel, M.D. as President of Global Research.
Celgene Names David W. Gryska Chief Financial Officer.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters